Question

a small protein binds to the active site of an enzyme and causes an autoimmune disease. a treatment drug for the disease was discovered by a group of scientists by developing a molecule that has a structure very similar to the small protein. increasing the dose of the treatment drug can prevent the binding of small protein to the enzyme. what is the mode of action of the treatment drug?

Answer 1

The mode of action of the treatment drug can be described as competitive inhibition. Competitive inhibition occurs when a molecule, in this case, the treatment drug, competes with another molecule (the small protein) to bind to the active site of an enzyme.

Step-by-step explanation:

In this scenario, the small protein binds to the active site of the enzyme and triggers an autoimmune disease. The treatment drug developed by scientists has a structure very similar to the small protein. When administered at an appropriate dose, it outcompetes the small protein for binding to the active site of the enzyme.

By increasing the dose of the treatment drug, more molecules of it are available to bind to the active sites on the enzyme. This effectively prevents or reduces the binding of small proteins to those active sites. As a result, the autoimmune response triggered by the binding of small proteins is inhibited or suppressed.